APA (7th ed.) Citation

Daniel, A., Ghez, D., Ravaiau, C., Cavalieri, D., Tournilhac, O., Herbaux, C., . . . Terriou, L. (2022). Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma. European Journal of Haematology, 109(6), 719. https://doi.org/10.1111/ejh.13858

Chicago Style (17th ed.) Citation

Daniel, Adrien, et al. "Ibrutinib as a Treatment of Hematologic Autoimmune Disorders in Patients with Indolent B‐cell Lymphoma." European Journal of Haematology 109, no. 6 (2022): 719. https://doi.org/10.1111/ejh.13858.

MLA (9th ed.) Citation

Daniel, Adrien, et al. "Ibrutinib as a Treatment of Hematologic Autoimmune Disorders in Patients with Indolent B‐cell Lymphoma." European Journal of Haematology, vol. 109, no. 6, 2022, p. 719, https://doi.org/10.1111/ejh.13858.